Literature DB >> 10233840

Multiplex Western blotting system for the analysis of muscular dystrophy proteins.

L V Anderson1, K Davison.   

Abstract

A multiplex system of Western blotting is presented in which most of the current muscular dystrophy proteins can be analyzed simultaneously on one pair of blots. This represents a significant improvement in efficiency and cost for this type of analysis. The final diagnosis is more quickly achieved in patients where several possible diagnoses are indicated after clinical appraisal, and those with unusual presentations may be quickly resolved. The method uses a biphasic polyacrylamide gel system, which enables the corresponding blot to be probed simultaneously with a cocktail of monoclonal antibodies. The gel is optimized so that large proteins of more than 200 kd (eg, dystrophin, dysferlin, and myosin heavy chain) can be analyzed in the top part, while smaller proteins under 150 kd (eg, calpain 3, the 80-kd fragment of laminin alpha2 chain, all of the sarcoglycans, and caveolin 3) are separated in the lower phase. This basic system could be used for different combinations of antibodies as new muscular dystrophy proteins are identified and require examination. In addition, analysis of the laminin alpha2 chain of merosin showed that this protein was expressed as a doublet or triplet set of bands in many patients with active muscle pathology. This may indicate the existence of an embryonic isoform, which is re-expressed in regenerating fibers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233840      PMCID: PMC1866550          DOI: 10.1016/S0002-9440(10)65354-0

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  13 in total

1.  Late onset muscular dystrophy with cerebral white matter changes due to partial merosin deficiency.

Authors:  E Tan; H Topaloglu; C Sewry; Y Zorlu; I Naom; S Erdem; M D'Alessandro; F Muntoni; V Dubowitz
Journal:  Neuromuscul Disord       Date:  1997-03       Impact factor: 4.296

2.  A two-step procedure for efficient electrotransfer of both high-molecular-weight (greater than 400,000) and low-molecular-weight (less than 20,000) proteins.

Authors:  T Otter; S M King; G B Witman
Journal:  Anal Biochem       Date:  1987-05-01       Impact factor: 3.365

3.  Early presentation of X-linked Emery-Dreifuss muscular dystrophy resembling limb-girdle muscular dystrophy.

Authors:  F Muntoni; E J Lichtarowicz-Krynska; C A Sewry; S Manilal; D Recan; S Llense; J Taylor; G E Morris; V Dubowitz
Journal:  Neuromuscul Disord       Date:  1998-04       Impact factor: 4.296

4.  Early onset autosomal dominant myopathy with rigidity of the spine: a possible role for laminin beta 1?

Authors:  J Taylor; F Muntoni; S Robb; V Dubowitz; C Sewry
Journal:  Neuromuscul Disord       Date:  1997-06       Impact factor: 4.296

5.  Abnormal merosin in adults. A new form of late onset muscular dystrophy not linked to chromosome 6q2.

Authors:  K Bushby; L V Anderson; C Pollitt; I Naom; F Muntoni; L Bindoff
Journal:  Brain       Date:  1998-04       Impact factor: 13.501

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Heterogeneity of dystrophin expression in patients with Duchenne and Becker muscular dystrophy.

Authors:  L V Nicholson; M A Johnson; D Gardner-Medwin; S Bhattacharya; J B Harris
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

8.  Abnormalities in alpha-, beta- and gamma-sarcoglycan in patients with limb-girdle muscular dystrophy.

Authors:  C A Sewry; J Taylor; L V Anderson; E Ozawa; R Pogue; F Piccolo; K Bushby; V Dubowitz; F Muntoni
Journal:  Neuromuscul Disord       Date:  1996-12       Impact factor: 4.296

9.  Dystrophin in skeletal muscle. I. Western blot analysis using a monoclonal antibody.

Authors:  L V Nicholson; K Davison; G Falkous; C Harwood; E O'Donnell; C R Slater; J B Harris
Journal:  J Neurol Sci       Date:  1989-12       Impact factor: 3.181

10.  Characterization of monoclonal antibodies to calpain 3 and protein expression in muscle from patients with limb-girdle muscular dystrophy type 2A.

Authors:  L V Anderson; K Davison; J A Moss; I Richard; M Fardeau; F M Tomé; C Hübner; A Lasa; J Colomer; J S Beckmann
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

View more
  38 in total

1.  Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy.

Authors:  Ingrid E C Verhaart; Hans Heemskerk; Tatyana G Karnaoukh; Ingrid G M Kolfschoten; Anne Vroon; Gert-Jan B van Ommen; Judith C T van Deutekom; Annemieke Aartsma-Rus
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

2.  Pharmacological inhibition of HSP90 activity negatively modulates myogenic differentiation and cell survival in C2C12 cells.

Authors:  Akira Wagatsuma; Masataka Shiozuka; Naoki Kotake; Kawachi Takayuki; Honda Yusuke; Kunihiko Mabuchi; Ryoichi Matsuda; Shigeru Yamada
Journal:  Mol Cell Biochem       Date:  2011-07-08       Impact factor: 3.396

3.  Utrophin is lacking at the neuromuscular junctions in the extraocular muscles of normal cat: artefact or true?

Authors:  Maziar Assadi; Markus Müntener
Journal:  Histochem Cell Biol       Date:  2005-02-24       Impact factor: 4.304

4.  A cross section of autosomal recessive limb-girdle muscular dystrophies in 38 families.

Authors:  P Dinçer; Z Akçören; E Demir; I Richard; O Sancak; G Kale; S Ozme; A Karaduman; E Tan; J A Urtizberea; J S Beckmann; H Topaloğlu
Journal:  J Med Genet       Date:  2000-05       Impact factor: 6.318

5.  Sodium nitrate alleviates functional muscle ischaemia in patients with Becker muscular dystrophy.

Authors:  Michael D Nelson; Ryan Rosenberry; Rita Barresi; Evgeny I Tsimerinov; Florian Rader; Xiu Tang; O'Neil Mason; Avery Schwartz; Thomas Stabler; Sarah Shidban; Neigena Mobaligh; Shomari Hogan; Robert Elashoff; Jason D Allen; Ronald G Victor
Journal:  J Physiol       Date:  2015-11-02       Impact factor: 5.182

6.  Novel deletion of lysine 7 expands the clinical, histopathological and genetic spectrum of TPM2-related myopathies.

Authors:  Ann E Davidson; Fazeel M Siddiqui; Michael A Lopez; Peter Lunt; Heather A Carlson; Brian E Moore; Seth Love; Donald E Born; Helen Roper; Anirban Majumdar; Suman Jayadev; Hunter R Underhill; Corrine O Smith; Maja von der Hagen; Angela Hubner; Philip Jardine; Andria Merrison; Elizabeth Curtis; Thomas Cullup; Heinz Jungbluth; Mary O Cox; Thomas L Winder; Hossam Abdel Salam; Jun Z Li; Steven A Moore; James J Dowling
Journal:  Brain       Date:  2013-02       Impact factor: 13.501

7.  Role of dystroglycan in limiting contraction-induced injury to the sarcomeric cytoskeleton of mature skeletal muscle.

Authors:  Erik P Rader; Rolf Turk; Tobias Willer; Daniel Beltrán; Kei-Ichiro Inamori; Taylor A Peterson; Jeffrey Engle; Sally Prouty; Kiichiro Matsumura; Fumiaki Saito; Mary E Anderson; Kevin P Campbell
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-13       Impact factor: 11.205

8.  Anoctamin 5 muscular dystrophy in Denmark: prevalence, genotypes, phenotypes, cardiac findings, and muscle protein expression.

Authors:  Nanna Witting; Morten Duno; Helle Petri; Thomas Krag; Henning Bundgaard; Lars Kober; John Vissing
Journal:  J Neurol       Date:  2013-05-14       Impact factor: 4.849

9.  Duchenne and Becker muscular dystrophy: contribution of a molecular and immunohistochemical analysis in diagnosis in Morocco.

Authors:  Hanane Bellayou; Khalil Hamzi; Mohamed Abdou Rafai; Mehdi Karkouri; Ilham Slassi; Houssine Azeddoug; Sellama Nadifi
Journal:  J Biomed Biotechnol       Date:  2009-05-19

10.  New aspects on patients affected by dysferlin deficient muscular dystrophy.

Authors:  Lars Klinge; Ahmed Aboumousa; Michelle Eagle; Judith Hudson; Anna Sarkozy; Gianluca Vita; Richard Charlton; Mark Roberts; Volker Straub; Rita Barresi; Hanns Lochmüller; Kate Bushby
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-06-14       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.